Gossamer Bio, Inc. (GOSS) Balance Sheet
As of 2026-06-30 (10-Q), Gossamer Bio, Inc. (GOSS) reported total assets of $76.9M, total liabilities of $170.9M and shareholders' equity of -$94.0M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $41.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GOSSGossamer Bio, Inc.Follow GOSS — free
—
Price chart with a free account
- Market cap
- 4.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 135.0 | 486.1 | 183.4 | 112.0 | 32.1 | 46.1 | 37.7 | 41.1 | |
| Short-term investments | 266.7 | 26.6 | 141.8 | 143.7 | 264.3 | 248.4 | 99.2 | 15.9 | |
| Receivables | — | — | — | — | 0.0 | 5.3 | 12.2 | 6.1 | |
| Current assets | 409.3 | 522.3 | 331.8 | 261.9 | 306.5 | 309.9 | 167.6 | 72.7 | |
| Total assets | 426.6 | 539.4 | 343.7 | 272.5 | 311.9 | 315.3 | 172.2 | 76.9 | |
| Current liabilities | 36.9 | 38.7 | 39.9 | 49.2 | 51.6 | 45.0 | 63.4 | 137.8 | |
| Long-term debt | 28.5 | 28.7 | 29.1 | 12.0 | 0.8 | 0.0 | — | — | |
| Short-term debt | — | — | 0.0 | 11.6 | 11.6 | 0.0 | — | — | |
| Total liabilities | 74.1 | 218.7 | 222.2 | 260.4 | 249.1 | 285.8 | 295.0 | 170.9 | |
| Shareholders' equity | 352.5 | 320.7 | 121.5 | 12.1 | 62.8 | 29.5 | -122.8 | -94.0 |
USD millions · SEC XBRL
Gossamer Bio, Inc. — questions
- How much cash does Gossamer Bio, Inc. have?
- $41.1M in cash and cash equivalents as of 2026-06-30.
- What are Gossamer Bio, Inc.'s total assets?
- $76.9M as of 2026-06-30.
- What is Gossamer Bio, Inc.'s shareholders' equity?
- -$94.0M as of 2026-06-30.
Every figure on this page comes from Gossamer Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.